Yes. ACV does not have a corresponding monograph in Health Canada's Natural Health Products Ingredients Database (NHPID). Because there is no monograph to reference, any NPN application for an ACV-based natural health product must follow the Class III pathway, which requires the applicant to independently provide scientific evidence supporting the ingredient's safety and efficacy. This cannot be bypassed by reformulating or changing the dosage form. 

The official Health Canada service standard for Class III applications is 210 days. In practice, total timelines often range from 6 months to over 1.5 years, depending on the completeness of the submission, the reviewer's workload, and whether Information Request Notices (IRNs) are issued. In our documented ACV case study, approval was received in under 10 months from the date of submission, which is faster than average for a Class III application. 

The primary reason is the Class III regulatory barrier. Because ACV lacks a monograph in the NHPID, brands cannot follow a standardized application path. Instead, they must build a complete scientific dossier from scratch. Combined with the long processing timeline and the risk of the product being classified as a food rather than a natural health product, many brands choose not to pursue NPN licensing and instead sell ACV products as unregulated food items — which means they cannot legally make health claims on the label or in advertising.

Yes. This is one of the most common grounds for refusal in ACV applications. If the claimed health function is too general — for example, "increases satiety" or "supports digestion" — a Health Canada reviewer may determine that the product does not meet the threshold for NHP classification and reject the application, advising the applicant to sell the product as a food instead. To avoid this outcome, the claimed function must be specific enough to clearly distinguish the product from ordinary food use, while still being supported by available scientific literature.

Approved health claims must be listed on the NPN licence issued by Health Canada and must be supported by the evidence submitted during the application. In our case study, the primary clam approved was antioxidant activity, with additional claims relating to metabolic support obtained through a co-ingredient with an existing Health Canada monograph. Claims such as weight loss, blood sugar regulation, or antimicrobial activity carry significantly higher evidentiary requirements and refusal risk, and are not recommended as primary claims for ACV applications without robust clinical data.

An IRN is a formal written request from Health Canada asking the applicant to clarify, correct, or supplement specific elements of their submission. Receiving one or more IRNs during a Class III review is normal and does not indicate that an application will be refused. In our ACV case study, two IRNs were received — one related to literature documentation and one related to dosage safety clarification — and both were resolved successfully without triggering reformulation or claim changes. The key is responding accurately and promptly.

Yes, and this is frequently overlooked by applicants. Health Canada's review process places significant weight on safety documentation. If other licensed NHP products containing the same medicinal ingredient carry specific warnings — such as cautions for people with certain health conditions or interactions with medications — and your application does not include equivalent statements, this inconsistency may result in an IRN or refusal. Including proactive, evidence-based risk statements in your submission strengthens the application and demonstrates that the product has been thoroughly evaluated.

Yes, and this is a common and legitimate strategy. By including co-ingredients that have existing Health Canada monographs, you can obtain approved claims for those ingredients within the same NPN licence. This is particularly useful when the primary ingredient (such as ACV) lacks a monograph and therefore cannot support certain claims on its own. In our case study, a co-ingredient with an existing monograph was added specifically to support metabolic claims that aligned with the client's marketing objectives, while keeping the evidentiary risk of the application low.

Health Canada classifies NPN applications into three categories based on risk and complexity. Class I applications follow an existing monograph exactly and are typically processed within 10 days. Class II applications mostly follow a monograph with minor deviations and are processed within 60 days. Class III applications involve ingredients or formulations with no applicable monograph, novel delivery systems, or significant safety considerations requiring full scientific review, with a service standard of 210 days. ACV applications fall into Class III because no ACV monograph exists in the NHPID.

PinPoint North provides Health Canada NPN regulatory consulting for natural health product brands, including Class III applications for ingredients without an existing monograph. Services include ingredient feasibility assessment, claim strategy development, evidence package preparation, and IRN response support. Contact us at pinpointnorth.com.